Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Kim on the Evolving Treatment Landscape of Advanced HCC

August 14th 2020

Richard D. Kim, MD, discusses the evolving treatment landscape of advanced hepatocellular carcinoma.

Dr. VanderWalde on Future Research in Rectal Cancer

August 13th 2020

Noam VanderWalde, MD, MS, discusses where future research efforts should focus in rectal cancer.

Dr. Halfdanarson on Molecular Differences Between Left- Versus Right-Sided Tumors in CRC

August 12th 2020

Thorvardur (Thor) Halfdanarson, MD, discusses the molecular differences between left- versus right-sided tumors in colorectal cancer.

Nivolumab Plus Chemotherapy Shows Significant Survival Benefit in Gastric and Esophageal Cancers

August 11th 2020

Nivolumab in combination with chemotherapy as a frontline treatment demonstrated a significant survival benefit in patients with metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma

Adjuvant Nivolumab Significantly Improves DFS in Resected Esophageal or GEJ Cancer

August 11th 2020

Nivolumab, following neoadjuvant chemoradiation and complete surgical resection, resulted in a statistically significant improvement in disease-free survival in patients with resected esophageal or gastroesophageal junction cancer.

Dr. Mehta on the Evolution of Treatment in Gastric and GEJ Cancers

August 11th 2020

Rutika J. Mehta, MD, MPH, discusses how treatment has evolved in recent years for gastric and gastroesophageal junction cancers.

Dr. VanderWalde on Personalizing Therapy in Rectal Cancer

August 10th 2020

Noam VanderWalde, MD, MS, discusses the push toward personalizing therapy in rectal cancer.

Pancreatic Cancer Updates

August 10th 2020

Liver Cancer Updates

August 10th 2020

Gastric Cancer Updates

August 10th 2020

Colorectal Cancer Updates

August 10th 2020

Phase 3 OPTIMA Trial in HCC to Continue to Follow Patients for OS

August 4th 2020

Celsion Corporation will continue to follow patients with hepatocellular carcinoma enrolled on the phase 3 OPTIMA trial examining ThermoDox® in combination with radiofrequency ablation for overall survival.

Ripretinib Granted Priority Review in China for Advanced GIST

August 4th 2020

China’s National Medical Products Administration has granted priority review status to a new drug application for ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumor who received previous treatment with 3 or more kinase inhibitors, including imatinib.

Blood-Based Assay Could Soon Surface in Colorectal Cancer

August 4th 2020

Shai Friedland, MD, discusses the novel multimodal FirstSight test, which showed promise in identifying colorectal cancer, as well as precancerous polyps and advanced adenomas.

KEYNOTE-177 Cements Pembrolizumab as New Standard of Care in MSI-H/dMMR mCRC

August 4th 2020

Thierry Andre, MD, discusses the results of the KEYNOTE-177 trial in metastatic colorectal cancer.

Adding Celecoxib to FOLFOX Does Not Demonstrate DFS Benefit in Colon Cancer

August 4th 2020

Jeffrey A. Meyerhardt, MD, MPH, FASCO, discusses the addition of celecoxib to standard chemotherapy, stating that it did not significantly improve disease-free survival or overall survival in patients with colon cancer.

Dr. Kundranda on the Need for Novel Treatments in Pancreatic Ductal Adenocarcinoma

August 3rd 2020

Madappa Kundranda, MD, PhD, discusses the need to develop novel treatments in pancreatic ductal adenocarcinoma.

FDA Grants SM-88 Orphan Drug Status for Pancreatic Cancer

August 3rd 2020

The FDA granted an orphan drug designation to the oral investigational modified proprietary tyrosine derivative SM-88 as a treatment for patients with pancreatic cancer.

Ripretinib Approval Advances Recurrent GIST Paradigm

August 3rd 2020

Ripretinib has become the first therapy specifically approved for the fourth-line treatment of gastrointestinal stromal tumors, a clinical setting with an unmet medical need because of the poor prognosis of patients with progressive disease.

Making Up for Lost Time in GI Cancers

August 3rd 2020

Tanios S. Bekaii-Saab, MD, discusses how the field of gastrointestinal cancers is gaining ground with regard to the development of targeted and immunotherapy agents.